Infinimmune Raises $75 Million Series A to Advance Human-Derived Antibody Pipeline for Atopic Dermatitis

Infinimmune, a biotechnology company developing antibody therapeutics derived directly from the human immune system, announced the closing of a $75 million Series A financing co-led by Regeneron Ventures and Playground Global.¹ Participating investors included RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, and Wild Tree Ventures, alongside existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures, and Pear VC.¹ The financing will support clinical development of Infinimmune's two lead atopic dermatitis programs, advance additional pipeline candidates, and fund continued deployment of the company's Anthrobody antibody discovery platform.¹

What is in Infinimmune's pipeline?

Infinimmune is advancing two wholly owned, half-life-extended monoclonal antibodies targeting complementary pathways in atopic dermatitis, both expected to enter the clinic in 2027.¹ IFX-101 targets interleukin-22 (IL-22), a cytokine pathway the company describes as having no approved biologic; IL-22 has been shown to correlate with atopic dermatitis disease severity and to contribute to epidermal hyperplasia and skin barrier dysfunction through effects on keratinocytes.² IFX-201 targets interleukin-13 (IL-13), a pathway already addressed by approved biologics including tralokinumab and lebrikizumab, though Infinimmune is positioning IFX-201 as a potentially best-in-class option with more convenient dosing.² IL-13 works alongside IL-4 as a central driver of the type 2 immune response underlying atopic dermatitis. Research has also shown that IL-13 downregulates IL-22 signaling, indicating some degree of interaction between the two pathways.²

How does the Anthrobody platform work?

Infinimmune's Anthrobody platform screens millions of single memory B cells across hundreds of targets to identify natively paired, fully human antibodies, an approach the company positions as an alternative to conventional antibody engineering.¹ The platform is paired with GLIMPSE, a protein language model trained on native human antibody sequences that guides candidate selection and optimization.¹ In March 2026, Infinimmune entered a multi-target antibody discovery collaboration with Merck that includes up to approximately $838 million in upfront and potential milestone payments.¹

What did company leadership and investors say?

Wyatt McDonnell, PhD, co-founder and chief executive officer of Infinimmune, said, "The human immune system makes extraordinary antibodies. We built a company to find them and are uniquely positioned to turn them into transformative medicines for patients with unmet needs. This financing enables Infinimmune to bring that promise to the clinic, as we work alongside a world-class syndicate to develop the molecules that patients living with inflammatory diseases deserve."¹ Benjamin Kim, PhD, partner at Playground Global, said, "Infinimmune's Anthrobody platform produces antibodies with a combination of potency, half-life, and developability that we haven't seen from conventional discovery approaches, and does so in a fraction of the time when compared to traditional technologies."¹

What did an outside clinical expert say about the pipeline's disease relevance?

Emma Guttman, MD, PhD, system chair of the department of dermatology and Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, whose translational research helped define the roles of IL-13 and IL-22 in atopic dermatitis, said, "Ten years after the first systemic biologics received approval, achieving complete and durable disease control continues to be an elusive goal for many patients. IFX-101 targets IL-22, a pathway with no approved biologic, while IFX-201 delivers potentially best-in-class IL-13 neutralization and dosing convenience. Together, these programs offer the breadth to address complementary axes of disease and the opportunity to redefine what clear skin can mean for patients."¹

References

1. Infinimmune raises $75 million Series A financing to advance pipeline of human-derived antibodies for atopic dermatitis and inflammatory disease. News release. Business Wire. August 13, 2026. Accessed August 13, 2026.
2. D'Avino P, et al. Distinct roles of IL-4, IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis. Allergy. 2026. doi:10.1111/all.70060